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 Abstract 
Fecal calprotectin (FC) is a calcium-binding protein with antimicrobic, imunomodulatory 
and antiproliferative properties that is mainly found in the cytoplasm of neutrophil granulocytes. 
During the last decades, FC became an increasingly useful tool both for gastroenterologists and for 
general practitioners for distinguishing inflammatory bowel disease (IBD) from irritable bowel 
syndrome. FC correlates with clinical scoring systems and endoscopic lesions in IBD and is 
considered a reliable biomarker for the prediction of clinical relapse or remission. However, FC 
elevation could be observed also in other gastrointestinal pathological conditions including infective 
colitis, microscopic colitis, eosinophilic colitis, adenomas and colorectal cancer. In addition, there 
are several non-pathological conditions that can lead to altered FC values.  
In this review, we aimed to point out individual, environmental and method-related factors 
that can affect FC measurement and thus its clinical interpretation. 
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 Calprotectin is a 36.5 KDa calcium- and zinc-binding protein that belongs to the S-100 
protein family.1 Calprotectin is mainly found in neutrophil granulocytes accounting for up to 60% 
of the cytosolic proteins but also in monocytes, macrophages and epithelial cells. Calprotectin has 
several biological properties including antimicrobic, immunomodulatory and antiproliferative 
activities, and it is released during cell activation (active release) or cell death (passive release).2,3 
The accumulation of neutrophils in the mucosa, a feature of inflammatory flares, results in the 
release of fecal calprotectin (FC) in the stools, where it can be easily measured. In particular, the 
presence of calprotectin in feces quantitatively relates to neutrophil migration toward the 
gastrointestinal (GI) tract; thus, it represents a useful marker of intestinal inflammation also because 
unlike other systemic inflammatory markers, its levels seem to be unaffected by causes of 
inflammation other than intestinal ones. 
 Until 1990, calprotectin was known as leucocyte protein 1 (L1); afterwards, Steinbakk et al 
observed that the calcium binding L1 protein was able to inhibit the growth of blood culture isolates 
of Candida spp and several gram-positive and -negative bacteria.4 Due to the biological activity of 
L1, the name calprotectin was proposed to describe this antimicrobial protein with calcium binding 
properties.4 Subsequently, Roseth et al described a method for the extraction and the quantification 
of calprotectin in feces by enzyme immunoassay, observing that FC was stable in stool for 7 days at 
room temperature and it was resistant to bacterial proteolytic degradation;5 even more, FC was able 
to accurately reflect granulocyte migration through the gut wall in patients with inflammatory 
bowel disease (IBD).6 Before these discoveries, fecal excretion of indium-111-labelled neutrophilic 
granulocytes was considered the gold standard of disease activity, but its complexity and high cost 
and the exposure of patients to ionizing irradiation had limited the use of this technique.6 
Since 2000, numerous studies have been published showing evidence regarding FC 
usefulness for the detection and monitoring of a several GI disorders, especially IBD: a clear 
relationship has been demonstrated between the magnitude of calprotectin elevation and the extent 
of intestinal inflammation 7-9 Indeed, in clinical practice differentiating patients with organic 
diseases from those with functional disorders (i.e. irritable bowel syndrome [IBS]) may be difficult 
because of a wide spectrum of overlapping symptoms including abdominal pain, bloating, diarrhea, 
constipation or altered bowel habit.10-12 However, it should be noted that elevated FC levels could 
be found not only in IBD but also in other GI pathological conditions including infective colitis, 
microscopic colitis, eosinophilic colitis, adenomas and colorectal cancer.13-17 FC showed high 
correlation with bacteriologically positive infectious diarrhoea, with sensitivity and specificity 
being 83% and 87% respectively.18 The high levels of FC in active collagenous colitis (CC) patients 
can be explained by the fact that calprotectin is present not only in neutrophils but also in 
monocytes and macrophages; nevertheless, the use of FC as an inflammatory marker for CC is not 
recommended for lack of universal evidence.19 Tursi et al showed that FC were significantly 
increased in 16 participants with acute uncomplicated diverticulitis and in 16 participants with 
symptomatic uncomplicated  diverticular disease (SUDD), compared with 16 patients with 
asymptomatic diverticulosis; FC decreased to normal values after treatment, both in acute 
uncomplicated diverticulitis and in SUDD.20 
In addition, there are several non-pathological conditions, including individual, 
environmental and method-related factors, that can lead to altered FC values and in turn, that can 
mislead the clinical evaluation (Table I). 
 
Fecal calprotectin cut-off in clinical practice 
Currently, a FC result below 50 µg/g is considered normal. According to a recent meta-
analysis, FC <50 µg/g gave a pooled sensitivity (Se) of 93% and specificity (Sp) of 94% for 
distinguishing between IBD and IBS in adults.21 In a primary care setting, Pavlidis et al reported 
that among 962 patients (18-45 years) with persistent GI symptoms, 686 (71%) patients had 
negative (<50 μg/g) FC results whereas 276 (29%) tested positive (>50 µg/g).22 This cut-off showed 
Se=82% and Sp=77% for organic diseases, with a negative predictive value (NPV) and positive 
predictive value (PPV) of 98% and 28%, respectively.23 So far, a cut-off of 50 µg/g could be 
suggested in order to rule out patients with IBS. 
Conversely, in a secondary/tertiary care setting higher cut-off values of FC may be 
recommended.20 Among 68 patients referred to our outpatient clinic for the first time and reporting 
abdominal pain and/or altered bowel habits lasting at least 4 weeks, we showed that a cut-off of 150 
µg/g was able to classify correctly 90% of IBS cases and 88% of IBD cases with an area under the 
curve (AUC) of 0.931, indicating an excellent diagnostic accuracy; however the performance was 
lower for the discrimination between functional and organic diseases (AUC=0.811).14 In addition, 
Dhaliwal et al showed Se=90% in determining IBD remission (AUC=0.93) by using a cut-off less 
than 250 µg/g.24 In Crohn disease, FC levels >250 μg/g indicated the presence of large ulcers with a 
sensitivity of 60.4% and a specificity of 79.5% (PPV=78.4%, NPV=62.0%).25 
 
Individual and environmental factors affecting fecal calprotectin levels 
Apart from intestinal organic diseases, several individual and environmental factors are 
associated to increased FC values. Among demographic features, it has been reported that age less 
than 4 years is negatively correlated with FC levels.26 Song et al investigated FC levels in a cohort 
of healthy children aged between 6 months and 4 years and found that the 95th percentile of FC 
values was 135 μg/g in 7-12 months group, 65 μg/g in 13-18 months group, 55 μg/g in 19-24 
months group, 40 μg/g in 25-30 months group, 21 μg/g in 31-36 months group, and 12 μg/g in 37-
48 months group.27 Oord et al compared FC levels of 75 healthy children (from 1 month to 4 years 
of age) with those of 157 children who have had a FC analysis performed for diagnostic purposes 
and, on the basis of the results observed, proposed three different cut-offs according to the different 
age groups: 538 µg/g (from 1 to 6 months), 214 µg/g (from 6 months to 3 years) and 75 µg/g (from 
3 to 4 years).28 However, it is noteworthy that also older age is associated with increased FC 
levels.29 Probably, the decline in cellular and humoral immunity associated to increased age may 
affect the maintenance of the gut mucosal immune integrity causing an increased inflammatory 
response towards different antigenic stimuli.30 
Elevated FC levels have been reported in individuals with increased body mass index 
(BMI).31-33 Interestingly, it has been showed that subjects with BMI > 25 Kg/m2 and FC > 50 µg/g 
undergoing a weight loss program experienced a reduction in FC levels.34 Moreover, obesity has 
been associated to both higher FC levels and fecal microbiota composition: obese subjects show a 
microbiota characterized by diminished bacterial diversity, a decreased ratio of Bacterioides to 
Firmicutes and higher FC levels.35 Since Paneth cells play a key role in the maintenance of the GI 
barrier,36 the diminished levels of Paneth cell derived antimicrobial proteins observed in obese 
subjects may partly explain the local intestinal inflammation.37 Finally, in a recent study 
investigating the potential relationship between lifestyle factors and colorectal cancer risk, authors 
observed that increased age, reduced physical activity and decreased fiber intake were significantly 
and independently associated to higher FC levels.29 Also, dietary supplements such as zinc, vitamin 
D, fatty acids, and several probiotics can affect FC levels.38 
Among confounding factors, the use of non-steroidal anti-inflammatory drugs (NSAID) and 
proton pump inhibitors (PPI) have been associated with FC elevation. NSAID-induced enteropathy 
is characterized by an increased influx of neutrophils to the intestinal mucosa and subsequent 
excretion into the bowel lumen, consequently leading to increased FC levels.39,40 Less clear is the 
mechanism causing FC elevation following PPI use. Poullis et al found that patients taking PPI had 
significantly elevated FC levels compared to those not on PPI (78 µg/g vs. 31 µg/g, p<0.001).41 
Moreover, the effect of PPI appeared to be independent from underlying dyspepsia; as authors 
reported, in patients not taking PPI, FC of those with no dyspepsia was not significantly different 
compared to FC of dyspeptic patients (30 µg/g vs. 31 µg/g, p>0.05).41 Based on this findings, 
discontinuation of PPI prior to FC testing may be suggested in order to increase the specificity for 
detecting organic GI disorders. 
 
Methods for fecal calprotectin assessment 
Before testing, FC needs to be extracted from stool. The “gold standard” is considered the 
manual weighing approach through which a portion of 50-100 mg of homogenized faecal material 
is diluted to achieve a weight-to-volume ratio of 1:50 using extraction buffer.5,42 Despite its 
reliability, this method is time consuming and consequently unsuitable for routine use. For this 
reason, different commercially available extraction devices have been developed, making pre-
analytical phase easier and faster. These extraction systems utilize a fixed volume of fecal material 
to equate a defined weight of stool and currently, completely replaced the manual extraction 
method.  
Regarding analytical phase, the most diffused method for FC measurement is the enzyme-
linked immunosorbent assay (ELISA) (Table II). This method employs a primary antibody, either 
monoclonal or polyclonal, to detect FC and a secondary enzyme-linked antibody that binds the 
primary immuno-complex. Following the formation of the “sandwich”, the enzyme converts the 
substrate generating a color; absorbance is spectrophotometrically red and converted in 
concentration based on a standard curve.43 The main advantages of this method are the analytical 
accuracy and the possibility to test simultaneously up to 80 samples (40, if tested in duplicate) in 
approximately 2 hours.  
Base on the same principle, novel chemiluminescent enzyme immunoassays (CLEIA) have 
been developed.44 Compared to traditional ELISA, CLEIA-based methods minimize waste of 
reagents and are fully automated, thereby reducing the workload for the laboratory personnel. In 
addition, CLEIA methods offer rapid turnaround times and are less demanding in technical 
expertise.  
During the last decade, novel rapid lateral-flow immunochromatographic methods for FC 
quantitation have been developed.45-47 In contrast to ELISA test, that are mostly confined to the 
medical laboratories, point-of-care tests (POCTs) are simple medical tests that can be performed at 
the bedside since not require specific and dedicated instrumentation. In addition, ELISA have long 
turnaround times, making POCTs more cost-effective. However, it is unclear what could be the 
added value of POCTs over sending stool specimens to a laboratory for the ELISA testing, 
considering that management and referral decisions for non-acute GI conditions are unlikely to need 
immediate answers from a FC test. 
 More recently, a novel particle enhanced turbidimetric immunoassay (PETIA) for FC 
quantitation have been proposed as a less expensive and a less labor intensive alternative method to 
traditional ELISA.48 Turbidimetry measure the loss of intensity of transmitted light due to the 
scattering effect of particles in a solution.49 The peculiarity of PETIA method is that can be applied 
on standard chemistry analyzers. 
 
Pre-analytical and analytical issues 
Concerning pre-analytical phase, potential source of variability in FC measurement is 
represented by characteristics of stool, within-day sampling time and extraction method.50 Lasson et 
al observed, in patients with active ulcerative colitis, that FC levels correlated significantly with 
both the time between bowel movements (r=0.50, p=0.013) and with the stool consistency (r=0.68, 
p=0.001).51 However, the latter feature could be a consequence of the disease activity. In fact, it has 
been reported in patients without intestinal organic disease that looser stool consistency was 
associated to lower FC levels,29 probably due to a sample dilution effect. In addition, looser stool 
consistency affects sample recovery thus leading to unreliable FC results.  
Devices used for sampling and extraction can affect FC results. Whitehead et al showed that 
extraction of faecal samples with three different commercial devices (Roche, ScheBo and 
Immunodiagnostik) led to an under-recovery of FC in comparison with the manual extraction 
procedure (overall mean bias from -28.1% to -7.8%).52 In addition, under sampling was particularly 
evident with watery stool.52 
Concerning methods of FC quantitation, several studies showed a significant degree of 
variability between assays. From a comparison of 3 ELISA methods emerged a significant assay 
discordance: Buhlmann-fCal® ELISA assay tended to give higher FC results (up to 3.8 fold) than 
the IDK® Calprotectin ELISA and Calprest® Eurospital assays.52 Labaere et al determined 
calprotectin by means of three rapid immunochromatographic tests (Quantum Blue® Bulhmann, 
Calfast® Eurospital, CerTest® Biotec) two ELISA assays (Calprest® Eurospital and CalproLab™ 
Calprotectin ELISA), and one automated fluoroimmunoassay (EliA® Calprotectin –Phadia); despite 
all methods correlated significantly, slopes and intercepts differed extensively, with up to 5-fold 
quantitative differences between assays.53 Delefortrie et al reported higher FC levels measured 
using the Quantum Blue® Bulhmann when compared to DiaSorin Liaison® Calprotectin, 
independently of the extraction method used.54 
Similarly, we performed a comparison of two ELISA assays (Calprest® Eurospital and 
Buhlmann-fCal® ELISA) on a total of 60 fecal samples collected from 23 outpatients with 
functional intestinal disorders and 37 with organic diseases (unpublished data). The two assays 
showed both high precision (Pearson ρ=0.9298) and high accuracy (Bias correction factor 
Cb=0.9199), with an overall concordance correlation coefficient of 0.8553. However, Buhlmann-
fCal® ELISA assay showed an overall overestimation of FC levels compared to Calprest® 
Eurospital assays (Figure 1).  
 
Conclusions 
FC is a reliable non-invasive tool for assessing intestinal inflammation and plays a relevant 
role in clinical practice. However, clinicians must be aware that FC levels could be affected by 
several non-pathological conditions, including individual, environmental and method-related 
factors. Thus, the following key messages may be highlighted for clinicians. 
Since age, BMI, lifestyle and diet could affect FC values, the laboratory results must always 
be interpreted according to the clinical context and in case of inconsistent results, FC measurement 
should be repeated.  
Different cut-off values may be adopted; in primary care setting, an FC result <50 µg/g is 
accurate to rule out an organic disease, whereas in secondary/tertiary care, higher cut-off may be 
recommended to enhance the PPV of the test and thus, to accurately identify patients requiring 
endoscopic examination. 
Concerning stool sampling, watery stool are unsuitable for FC testing. Despite FC is stable 
in stool up to 1 week at room temperature, it would be advisable to preserve the stool sample at 
+4°C until delivery in laboratory for analysis. Regarding methods used for FC assessment, a high 
degree of variability has been widely reported. Since no international standard is available, it is 
recommended to perform FC monitoring at the same laboratory.  
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 Table I. Individual, environmental and methodological factors affecting FC levels. 
 
Abbreviations: FC, fecal calprotectin; BMI, body mass index; NSAID, non-steroidal anti-
inflammatory drugs; PPI, proton pump inhibitors.
 Table II. Comparison of available methods for FC quantitation. 
 
Abbreviations: CLEIA, chemiluminescent enzyme immunoassay; FEC, fecal calprotectin; ELISA, 
enzyme-linked immunosorbent assay; FEIA, fluorescence enzyme immunoassay; PETIA, particle 
enhanced turbidimetric immunoassay; POCT, point of care testing. 
 Figure 1. Bland-Altman plot (A) and Correlation plot (B) of FC levels assessed by Calprest® 
Eurospital and Buhlmann-fCal® ELISA assays. 
 
Bland-Altman plot (A) shows the variation of mean FC levels between Calprest® Eurospital and 
Buhlmann-fCal® ELISA assays. Correlation plot (B) depicts the deviation of the Passing Bablock 
regression equation with the corresponding 95% confidence interval respect to the identity line 
(y=x). FC values are reported in µg/g.  
FC, fecal calprotectin; ELISA, enzyme linked immunosorbent assay. 
 
